Other languages Alzinova AB

Equities

ALZ

SE0007413455

Market Closed - Nasdaq Stockholm Other stock markets 08:59:53 03/05/2024 pm IST			5-day change	1st Jan Change
1.262 ^SEK	+12.28%		+9.17%	-58.42%

25/04	Sweden’s Alzinova Says CEO to Step Down by July-end	MT
25/04	Kristina Torfgård Leaves the CEO Position At Alzinova Ab, Effective July 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sweden’s Alzinova Says CEO to Step Down by July-end	25/04
Kristina Torfgård Leaves the CEO Position At Alzinova Ab, Effective July 31, 2024	25/04
Alzinova AB Completes In-Depth Analysis of Data from Part A of Alzinova's Phase 1B Study with the Vaccine Candidate ALZ-101	11/04
Alzinova AB Announces All Patients in the Extension Part of the Phase 1B Study Have Received Their Last Dose of ALZ-101	04/04
Sweden's Alzinova Names Interim CFO	08/03
Alzinova AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28/02
Alzinova Secures Regulatory Approval to Test Higher Dose of Vaccine Candidate in Ongoing Trial	13/02
Alzinova AB Receives Regulatory Approval to Evaluate A Higher Dose of the Vaccine Candidate Alz-101 in the Ongoing Phase 1B Study	13/02
Alzinova AB Announces Primary Analysis Confirms Positive Phase 1B Results with ALZ-101 against Alzheimer's	30/01
Alzinova AB Announces Positive Phase 1b Results with the Vaccine Candidate ALZ-101 Against Alzheimer's Disease	29/11
Alzinova AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02/11
EU Medicines Regulator OKs Alzinova's Clinical Development Program for Alzheimer's Drug Candidate	26/23/26
Alzinova AB Receives Positive Response from the European Medicines Agency EMA	26/23/26
Alzinova Enters Peptide Production Agreement with Manufacturer	25/23/25
Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	17/23/17
Alzinova Completes Pre-IND Meeting with US FDA on Alzheimer's Drug Candidate	09/23/09
Alzinova AB Successfully Concludes A Pre-IND Meeting with the US Food and Drug Administration Receiving Positive Feedback on the Planned Clinical Development Program for the Vaccine Candidate ALZ-101	09/23/09
Alzinova Appoints New Chief Medical Officer	03/23/03
Alzinova AB Appoints Kirsten Harting as New Chief Medical Officer, Effective from August 14, 2023	03/23/03
Alzinova AB Submits Request for Pre-IND Meeting with FDA and Applies for EMA Scientific Advice	13/23/13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Alzinova AB

Equities

ALZ

SE0007413455

Other languages

Filters